Inflammatory bowel disease (IBD) is an umbrella term for two diseases, Crohn’s disease and ulcerative colitis, which are associated with prolonged inflammation of the gastrointestinal tract. This condition often leads to the development of color tumors. Understanding the symptoms of IBD is important, therefore, it is important to reduce the incidence of cancer.
It appears that innate immune receptors, especially those expressed in the gut, such as C-type lectin receptors (CLRs), are responsible for the development of IBD. However, CLRs also play an important role in the regulation of the gut microbiota and protection against disease. As a result, balance is needed to maintain intestinal homeostasis.
Dendritic cell immunoreceptor (DCIR) is one such CLR that is responsible for maintaining the homeostasis of the immune system and the skeleton. Previous studies have suggested that DCIR does not properly regulate both the efficacy and the availability of immunity. Blocking DCIR can, therefore, improve intestinal immunity additive. However, its role in intestinal immunity remains unclear.
Based on this issue, the research group led by Professor Yoichiro Iwakura of Tokyo University of Science (TUS) in Japan shed more light on this issue. In their research, they will be published online on 2 August 2022 in the international journal Cell reportThe group studied the development of colitis and colon cancer rats The samples failed in the DCIR.
To this end, the team fed mice with drinking water containing dextran sodium sulfate (DSS), a sulfated synthetic polysaccharide, and azoxymethane (AOM), a neurotoxic chemical, to induce colon tumors similar to those seen in in people with IBD.
To their surprise, they found that DCIR-deficient mice showed less tumorigenesis and increased AOM-DSS color tumors. Moreover, when compared to the wild type (control), mice-negative mice showed less loss of human body and reduced number of viruses.
What do these observations mean? Prof. Iwakura explained that, “Our research shows that colon cancer and inflammation are facilitated by DCIR signaling, which suggests that blocking DCIR can prevent it. ulcerative colitis and colon cancer.”
Confirming this possibility, the study further revealed that the use of an antibody called “anti-NA2” against asialo-biantennary-N-glycans (NA2), the ligand (binding molecule) to DCIR, reduced the symptoms of DSS colitis also inhibited the development of colorectal cancer. .
The researchers were happy with these findings. Speaking about the application of their research, Professor Iwakura said, “Our results show that DCIR-targeted therapies can be used in combination to treat them effectively. autoimmune diseasesIBD, and cancer, which are traditionally difficult to treat.”
This research could open the doors to new therapeutic strategies to treat colorectal tumors, improving not only the survival of patients with IBD but also the understanding of human disease.
Yoichiro Iwakura, Blocking DCIR reduces colitis and prevents colorectal tumors by upregulating the GM-CSF-STAT5 pathway, Cell report (2022). DOI: 10.1016/j.celrep.2022.111158. www.cell.com/cell-reports/full … 2211-1247(22)00967-6
Tokyo University of Science
hint: Scientists discover new therapeutic target to treat colorectal tumors (2022, August 2) Retrieved 2 August 2022 from https://medicalxpress.com/news/2022-08-scientists-uncover-therapeutic-colorectal -tumors.html
This document is subject to copyright. Except for any bona fide transaction for research or investigation purposes, no part may be reproduced without written permission. Content is provided for informational purposes only.
Scientists uncover new therapeutic target for treating colorectal tumors Source link Scientists uncover new therapeutic target for treating colorectal tumors